Skip to main content

Table 2 Outcome of the neurological examinations, the symptom severity score and assessment of quality of life with doxycycline and placebo treatment

From: Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study

  Doxycycline 3 weeks Placebo 3 weeks
Patient no. Neurological examination SSS symptom 1/2 SF-36 PCS/MCS Neurological examination SSS symptom 1/2 SF-36 PCS/MCS
1 0 N.A +/+ 0 N.A −/−
2 + +/+ N.A 0 -/0 +/+
3 0 N.A −/+ 0 N.A N.A
4 0 0/0 +/− 0 0/0 N.A
5 0 +/− +/− 0 0/+ 0/+
6 0 0/+ −/− 0 0/0 N.A
7 0 0/+ N.A 0 0/- −/+
8 0 0/+ +/− 0 +/+ −/+
9 0 +/N.A +/+ 0 -/N.A −/+
10 0 +/+ +/+ + 0/+ −/+
11 0 0/0 −/+ + 0/0 −/+
12 0 0/0 −/− 0 0/+ +/−
13 0 -/0 −/+ + -/0 +/−
14 0 0/N.A −/+ 0 0/N.A N.A
15 0 0/0 +/− 0 0/0 +/+
  1. A difference between the results of the examinations and assessments after and before treatment was used for comparison of the outcome of treatment, and was defined as: +, improvement; 0, unchanged or –, worse. For the SSS, the two symptoms (symptom 1 and 2) with the highest severity scores were chosen for comparison. No significant differences were found in any of the outcome measures either within or between the doxycycline and placebo treatment groups. no, number; SSS, symptom severity score; SF-36, Short Form-36; PCS, physical component summary; MCS, mental component summary; N.A, not analyzed.